| Literature DB >> 25890291 |
Ngo Tat Trung1, Tran Thi Thu Hien2, Tran Thi Thanh Huyen3, Dao Thanh Quyen4, Mai Thanh Binh5, Phan Quoc Hoan6, Christian G Meyer7, Thirumalaisamy P Velavan8,9, Le Huu Song10,11.
Abstract
UNLABELLED: Surgical site infection (SSI) is common in Vietnamese post-operative patients. It contributes to increased morbidity, mortality, hospitalization time and health care expenditure. Bacterial culture is considered the gold standard procedure to identify SSI pathogens and antibiotic resistant properties; however, it can detect microbes that can readily grow and is time-consuming. We propose optimized multiplex PCR assays to diagnose the most relevant microbes and associated genes encoding for acquired extended spectrum betalactamases (ESBL) or carbapenemases from Vietnamese patients with SSI in a hospital setting in Hanoi.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25890291 PMCID: PMC4399146 DOI: 10.1186/s12941-015-0079-z
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Figure 1Multiplex PCR assays for screening of SSI associated microorganisms. Left panel MicroSHPT@5leX containing primers specific for Candida albicans, Acinetobacter baumanni, Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, whereas MicroSHPT@3leX amplify target genes specific for Klebsiella pneumonia Streptococcus pneumonia, Staphylococcus epidermidis. Control-1, control-2 are human whole blood genomics DNA.
Primer sequence used for screening of genes coding ESBL or carbapenemase
|
|
| ||
|---|---|---|---|
| 590 | SHPT108@CTX-M-U1-F | ATGTGCAGYACCAGTAARGTKATGGC | 0.4 |
| SHPT108@CTX-M-U2-R | GGTRAARTARGTSACCAGAAYCAGCGG | 0.4 | |
| 422 | SHPT108@TEM-U-F | TCGCCGCATACACTATTCTCAGAATGAC | 0.08 |
| SHPT108@TEM-U-R | CAGCAATAAACCAGCCAGCCGGAAG | 0.08 | |
| 739 | SHPT108@TR-SHV-F | TGTATTATCTC(C/T)CTGTTAGCC(A/G)CCCTG | 0.48 |
| SHPT108@TR-SHV-R | GCTCTGCTTTGTTATTCGGGCCAAGC | 0.48 | |
|
| |||
| 391 | SHPT108@TR-VIM-F | GATGGTGTTTGGTCGCATATCGCAAC | 0.08 |
| SHPT108@TR-VIM-R | CATCGCTGTTGGGGTTGCCCAATTTT | 0.08 | |
| 604 | SHPT108@TR-SPM-F | CTGGCAGGGATCGCTCACTC | 0.08 |
| SHPT108@TR-SPM-R | GGTTTCCGATCAGCCACCTCTCA | 0.08 | |
| 731 | SHPT108@NDM-1-F primer | CAGTGTGGGGGCCTGACGAT | 0.08 |
| SHPT108@NDM-1-R primer | CTGAGCA ACC TGC GCA ATR ATA GCT T | 0.08 | |
|
| |||
| 320 | SHPT108@TR-VIM-F | GATGGTGTTTGGTCGCATATCGCAAC | 0.04 |
| SHPT108@TR-VIM-R | CGAATGCGCAGCACCAGGATAGAA | 0.04 | |
| 291 | SHPT108@TR-SPM-F | CGTTTGAAAATCTGGGTACGCAAACG | 0.04 |
| SHPT108@TR-SPM-R | GTTTCAAATCAAAAACATTATCCGCTGGAACAG | 0.04 | |
| 200 | SHPT108@NDM-1-F primer | CGAAAGTCAGGCTGTGTTGCGC | 0.08 |
| SHPT108@NDM-1-R primer | GACCGCCCAGATCCTCAACTG | 0.08 | |
|
| |||
| 710 | SHPT108@Tr-DIM-F | TATTCAGCTTGTCTTCGCTTGCTAACG | 0.08 |
| SHPT108@Tr-DIM-R | GTTAGCGTTCGGCTGGATTGATTTG | 0.08 | |
| 412 | TR-KPC-BIC-F | GCTTTCT(T/G)GCTG(C/G)CGC(T/C)GTGCT | 0.2 |
| TR-KPC-BIC-R | AGCCAATCAAC(A/C)A(A/G)CTGCTG(C/A)CGC | 0.2 | |
| 326 | SHPT108@AIM-F | CCCTGAAGGTGTACGGAAACAC | 0.04 |
| SHPT108@AIM-R | GGGTTCGGCCACCTCGAATTG | 0.04 | |
| 204 | Tr-IMP-F | AC(G/A)GG(C/G/T)GGAATAGAGTGGCTTAA(T/C)TCTC | 0.02 |
| TR-IMP-R | TTCAGG(C/T)A(A/G)CCAAACYACTASGTTATCT | 0.02 | |
|
| |||
| 599 | SHPT108@Oxa-58-F | CCCCTCTGCGCTCTACATACAACATC | 0.08 |
| SHPT108@Oxa-58-R | AAGTATTGGGGCTTGTGCTGAGCATAG | 0.08 | |
| 482 | Tr-OXA-G23-F2 | AGAATATGT(G/C)CC(A/T)GC(C/A)TC(T/A)ACATTTAA(A/G)ATG | 0.2 |
| TR-OXA-G23-R2 | CCCA(G/A)CC(G/T)GT(C/T)AACCA(G/A)CC | 0.2 | |
| 286b | Tr-Oxa-G48-F2 | CACCAAGTCTTTAAGTGGGATGGACA | 0.08 |
| Tr-Oxa-G48-R2 | CCGATACGTGTAACTTATTGTGATACAGCTT | 0.08 | |
Target genes and primer sequences used for screeningof infectious microorganisms
|
|
|
|
|
|
|---|---|---|---|---|
| C | Z48339 | GTGGGTGGTAAATTCCATCTAAAGCTA | 243 | 0.2 |
| CCGTGCCACATTCCTCCGC | 0.2 | |||
| P. | AF116258 | CCCGAATGTCGGCATCATTCTC | 411 | 0.2 |
| CGGTAGACCTCGCGCTTGAA | 0.2 | |||
| S. | STAAROA | AAGGGCGAAATAGAAGTGCCGG | 515 | 0.2 |
| ATGGTCGGTTCCTTAGAAAACAAACTTG | .02 | |||
| A. | JX470958 | TTGGGGCCTTTGAGGCTTTAGTG | 599 | 0.2 |
| TGGTGCAACAAACTCCCATGGT | 0.2 | |||
| E. | S-uidA | GTCGCGAGTGAAGATCCCTTTC | 773 | 0.2 |
| GCATTAATGGACTGGATTGGGGC | 0.2 | |||
| K. | Kp-aldA | CCTTGTCTTTAAACGCGCGC | 332 | 0.2 |
| TTTTTCGCCGCAGCGG | 0.2 | |||
| S. | AF298800 | CGGTATCTTAGTTGTATCTGCTGC | 637 | 0.2 |
| AGATAATACGTATACTTCAGCTTTGAATTTTGTG | 0.2 | |||
| S. | Sp LytA | CAACCGTACAGAATGAAGCGGATTAT | 701 | 0.2 |
| GTCCTTGTACTTGACCCAGCCT | 0.2 |
Positive rates of Vietnamese SSI specimens detected by multiplex PCR assays and bacterial cultures
|
|
|
|
|---|---|---|
|
| 0 | 0 |
|
| 4 | 12 |
|
| 9 | 18 |
|
| 5 | 4 |
|
| 12 | 13 |
|
| 0 | 0 |
|
| 3 | 3 |
|
| 6 | 10 |
|
| 1 | 0 |
|
|
|
|
|
|
|
|
Figure 2Multiplex PCR assays for screening of acquired ESBL and carbapenemase encoding genes from SSI specimens. Upper left panel is SHPT@ESBL-1 assay to detect SHV, TEM, CTX-M genes; upper right panel is SHPT@ESBL-2 assay to detect VEB, GES, PER genes; lower left panel is SHPT@Carba-1 to screen for NDM, SPM, VIM and SHPT@Carba-2 to screen for IMP, AIM, KPC/BIC, DIM; lower right panel is SHPT@Carba-3 to screen for Oxa23 like group, Oxa48 like group, Oxa58 like group; control samples are human whole blood genomics DNA.
Genotypic prevalence of betalactamases detected from SSI specimens
|
|
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NKSM9 |
|
| Positive | Positive | Positive | Positive | |||||
| NKSM11 |
|
| Positive | Positive | Positive | Positive | |||||
| NKSM28 |
|
| Positive | Positive | Positive | Positive | Positive | Positive | Positive | ||
| NKSM33 |
|
| Positive | Positive | Positive | Positive | |||||
| NKSM40 |
|
| Positive | Positive | Positive | Positive | |||||
| NKSM49 |
|
| Positive | ||||||||
| NKSM53 |
|
| Positive | Positive | |||||||
| NKSM54 |
|
| Positive | ||||||||
| NKSM55 |
|
| Positive | ||||||||
| NKSM91 |
|
| Positive | Positive | Positive | ||||||
|
|
|
|
|
|
|
|
|
| |||